Metraipolis › archive › dc_22c95bdb5cfd

Druggable Mendelian randomization prioritizes CDH2 and supports finerenone as a candidate therapeutic strategy for diabetic retinopathy — Europe PMC PMID:42528538

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42528538
DOI
10.3389/fphar.2026.1865172
License (as archived)
solo-consultazione
Archived
2026-10-18T06:57:47.634Z
SHA-256 of the archived text
2f941039b43cb24e8890d2437574b3d0e44fc867377000b0509d4e33df612718
Stable URL of this page
https://metraipolis.com/documento/dc_22c95bdb5cfd

How to cite

Druggable Mendelian randomization prioritizes CDH2 and supports finerenone as a candidate therapeutic strategy for diabetic retinopathy — Europe PMC PMID:42528538 — Europe PMC (en), https://europepmc.org/article/MED/42528538 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_22c95bdb5cfd (Metraipolis archive dc_22c95bdb5cfd, sha256 2f941039b43cb24e8890d2437574b3d0e44fc867377000b0509d4e33df612718)
BibTeX
@misc{dc22c95bdb5cfd,
  title = {Druggable Mendelian randomization prioritizes CDH2 and supports finerenone as a candidate therapeutic strategy for diabetic retinopathy — Europe PMC PMID:42528538},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42528538},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_22c95bdb5cfd; sha256 2f941039b43cb24e8890d2437574b3d0e44fc867377000b0509d4e33df612718},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42528538. Agents can read the archived copy with the MCP tool read_document.